See more : MORI TRUST Sogo Reit, Inc. (8961.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cyteir Therapeutics, Inc. (CYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyteir Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- hhgregg, Inc. (HGGGQ) Income Statement Analysis – Financial Results
- Parmax Pharma Limited (PARMAX.BO) Income Statement Analysis – Financial Results
- Porto Seguro S.A. (PSSA3.SA) Income Statement Analysis – Financial Results
- General Environmental Conservation Public Company Limited (GENCO.BK) Income Statement Analysis – Financial Results
- LIGATT Security International, Inc. (LGTT) Income Statement Analysis – Financial Results
Cyteir Therapeutics, Inc. (CYT)
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 8.00K |
| Cost of Revenue | 1.38M | 479.00K | 351.00K | 12.69K |
| Gross Profit | -1.38M | -479.00K | -351.00K | -4.69K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -58.61% |
| Research & Development | 34.62M | 30.96M | 16.77M | 12.77M |
| General & Administrative | 13.55M | 11.30M | 4.18M | 3.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.55M | 11.30M | 4.18M | 3.35M |
| Other Expenses | 2.11M | 133.00K | 120.00K | -8.00K |
| Operating Expenses | 48.17M | 42.26M | 20.94M | 16.11M |
| Cost & Expenses | 48.17M | 42.26M | 20.94M | 16.11M |
| Interest Income | 0.00 | 133.00K | 120.00K | 246.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 668.00K | 479.00K | 351.00K | 215.00K |
| EBITDA | -47.50M | -41.78M | -20.59M | -15.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -198,625.00% |
| Operating Income | -48.17M | -42.26M | -20.94M | -16.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -201,312.50% |
| Total Other Income/Expenses | 2.11M | 133.00K | 120.00K | 1.06M |
| Income Before Tax | -46.06M | -42.13M | -20.82M | -15.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -188,050.00% |
| Income Tax Expense | -2.11M | -479.00K | 0.00 | 0.00 |
| Net Income | -43.95M | -41.65M | -20.82M | -15.04M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -188,050.00% |
| EPS | -1.25 | -2.14 | -0.87 | -0.77 |
| EPS Diluted | -1.25 | -2.14 | -0.87 | -0.77 |
| Weighted Avg Shares Out | 35.27M | 19.50M | 23.89M | 19.43M |
| Weighted Avg Shares Out (Dil) | 35.27M | 19.50M | 23.89M | 19.43M |
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a...
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled...
Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being investigated in combination with chemotherapy drugs. The drug has shown monotherapy activity in a...
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights. “We have made encouraging progress enrolling patients...
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights. “We continue to be...
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical...
Global Sepsis And Septic Shock Treatment Market Report 2022-2030: Expected Launch of Pipeline Drugs Such as MDX 1105, CYT-107, ALT-836, LB-1148, IFX-1 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Sepsis And Septic Shock Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering. This study report represents analysis of each...
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on...
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851...
2022 US, UK and Japan Nontuberculous Mycobacteria Market Size and Trend Report to 2031 - Players Include Revimmune, Novartis, Insmed and Nobelpharma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering. Diagnosed prevalent cases of Nontuberculous Mycobacteria (NTM)...
Source: https://incomestatements.info
Category: Stock Reports